Nuwellis Inc. (NUWE)
1.04
0.03 (2.97%)
At close: Jan 14, 2025, 3:59 PM
1.00
-4.31%
Pre-market Jan 15, 2025, 04:37 AM EST
undefined% (undefined)
| Bid | 1.07 |
| Market Cap | 4.57M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -60.77 |
| PE Ratio (ttm) | -0.02 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.08 |
| Volume | 118,513 |
| Avg. Volume (20D) | 2,660,972 |
| Open | 1.01 |
| Previous Close | 1.01 |
| Day's Range | 1.01 - 1.07 |
| 52-Week Range | 0.92 - 27.65 |
| Beta | undefined |
About NUWE
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products ...
Industry Medical - Devices
Sector Healthcare
IPO Date Feb 16, 2012
Employees 59
Stock Exchange NASDAQ
Ticker Symbol NUWE
Website https://www.nuwellis.com
Analyst Forecast
According to 1 analyst ratings, the average rating for NUWE stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 1526.79% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Nuwellis Inc. is scheduled to release its earnings on Mar 4, 2025,
before market opens.
Analysts project revenue of $2.56M, reflecting a 0.35% YoY growth and earnings per share of -0.59, making a -99.25% decrease YoY.
Analysts project revenue of $2.56M, reflecting a 0.35% YoY growth and earnings per share of -0.59, making a -99.25% decrease YoY.
4 weeks ago ·
Source
-17.86%
Nuwellis shares are trading lower after the compan...
Unlock content with
Pro Subscription
2 months ago ·
Source
+13.26%
Nuwellis shares are trading higher after the company reported better-than-expected Q3 revenue results.
